SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Guj. Themis Biosyn - Quaterly Results

04 Nov 2023 Evaluate
A decrease in the sales to Rs. 396.54 millions was observed for the quarter ended September 2023. The sales stood at Rs. 476.91 millions during the similar quarter previous year.Profit after Tax for the quarter ended September 2023 saw a decline of -32.93% from Rs. 186.99 millions to Rs. 125.42  millions.Operating Profit reported a sharp decline to 178.20 millions from 257.98 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 396.54 476.91 -16.85 892.42 926.35 -3.66 1489.73 1148.54 29.71
Other Income 10.01 13.96 -28.30 20.76 28.19 -26.36 60.24 40.50 48.74
PBIDT 178.20 257.98 -30.92 424.01 500.00 -15.20 802.42 620.96 29.22
Interest 0.51 0.42 21.43 0.76 1.04 -26.92 2.01 8.28 -75.72
PBDT 177.69 257.56 -31.01 423.25 498.96 -15.17 800.41 612.68 30.64
Depreciation 8.84 5.79 52.68 16.33 11.49 42.12 25.76 22.33 15.36
PBT 168.85 251.77 -32.93 406.92 487.47 -16.52 774.65 590.35 31.22
TAX 43.43 64.78 -32.96 104.29 122.77 -15.05 194.96 154.10 26.52
Deferred Tax 1.11 2.66 -58.27 2.07 0.74 179.73 2.55 0.72 254.17
PAT 125.42 186.99 -32.93 302.63 364.70 -17.02 579.69 436.25 32.88
Equity 72.64 72.64 0.00 72.64 72.64 0.00 72.64 72.64 0.00
PBIDTM(%) 44.94 54.09 -16.92 47.51 53.98 -11.97 53.86 54.07 -0.37

Guj. Themis Biosyn Share Price

319.45 15.45 (5.08%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×